GMV presents the final results of the SEPI-IA project, a groundbreaking AI-based solution for predicting the progression of lung diseases

GMV held an event to present the results of the SEPI-IA (Evolutionary Simulation of Interstitial Lung Disease with Artificial Intelligence) project, an R&D initiative carried out together with the Complutense University of Madrid (UCM) and in collaboration with leading hospitals, aimed at transforming the diagnosis and monitoring of interstitial lung diseases through artificial intelligence.

The event, held in the Grisolía auditorium at GMV’s Tres Cantos offices, featured a demonstration of the prototype developed by GMV and UCM, as well as a presentation of the results from the project’s various phases. La Paz University Hospital and Bellvitge University Hospital also shared their clinical assessment and discussed the tool’s potential impact on healthcare practice.

SEPI-IA is part of a Pre-Commercial Public Procurement initiative led by the Center for the Development of Industrial Technology (CDTI) and funded through the Recovery, Transformation, and Resilience Plan (PRTR) and the NextGenerationEU program.

The project addresses a growing need within Spain’s national health system: the need for tools that can predict the progression of diffuse interstitial lung diseases (DILDs), complex conditions where progression can vary significantly among patients.